Clinical Trial Update: Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study of idelalisib (IPI-145) in combination with Rituximab or Bendamustine/Rituximab in hematologic malignancies has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Lymphoma
• Non-hodgkin Lymphoma
• T-cell Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Idelalisib (idelalisib)
• Rituximab (rituximab)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Status: COMPLETED